Assessment of the potential role of Trefoil Factor-3 marker as a predictive marker of complication in splenectomized and non splenectomized patients with beta thalassemia major

1 Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood J Am Soc Hematol. 2010;115(22):43316. Search in Google Scholar

2 Sheiner E, Levy A, Yerushalmi R, Katz M. Beta-thalassemia minor during pregnancy. Obstet Gynecol. 2004;103(6):12737. Search in Google Scholar

3 Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008;31(Supplement_2):S262-8. Search in Google Scholar

4 Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood Rev. 2018;32(4):300-11. Search in Google Scholar

5 Attar S, Bakhshani Nm, Aliabad Qm. An investigation on the frequency of thoughts, readiness and suicide attempt in individuals with thalassemia. Pakistan J Med Heal Sci. 2021;15(6):1847-53. Search in Google Scholar

6 Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood, J Am Soc Hematol. 2010;115(10):1886-92. Search in Google Scholar

7 Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in β-thalassemia intermedia: breaking the silence. Thromb Res. 2012;130(5):695-702. Search in Google Scholar

8 Cappellini M, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the clinical management of thalassaemia. Nicosia (CY): Thalassaemia International Federation; 2014. Search in Google Scholar

9 Taher A, Vichinsky E, Musallam K, Cappellini M-D, Viprakasit V. Guidelines for the management of non transfusion dependent thalassaemia (NTDT). Nicosia: Thalassaemia International Federation; 2013. Search in Google Scholar

10 Bujak M, Bujak IT, Sobočanec S, Mihalj M, Novak S, Cosić A, et al. Trefoil Factor 3 deficiency affects liver lipid metabolism. Cell Physiol Biochem. 2018;47(2):827-41. Search in Google Scholar

11 Huang YG, Li YF, Wang LP, Zhang Y. Aberrant expression of trefoil factor 3 is associated with colorectal carcinoma metastasis. J Cancer Res Ther. 2013;9(3):376-80. Search in Google Scholar

12 Li Q, Wang K, Su C, Fang J. Serum Trefoil Factor 3 as a protein biomarker for the diagnosis of colorectal cancer. Technol Cancer Res Treat. 2017;16(4):440-5. Search in Google Scholar

13 Große-Kreul J, Busch M, Winter C, Pikos S, Stephan H, Dünker N. Forced Trefoil Factor Family Peptide 3 (TFF3) expression reduces growth, viability, and tumorigenicity of human retinoblastoma cell lines. PLoS One. 2016;11(9):1-21. Search in Google Scholar

14 Suemori S, Lynch-Devaney K, Podolsky DK. Identification and characterization of rat intestinal trefoil factor: tissue-and cell-specific member of the trefoil protein family. Proc Natl Acad Sci. 1991;88(24):11017-21. Search in Google Scholar

15 Xu L, Teng X, Guo J, Sun M. Protective effect of intestinal trefoil factor on injury of intestinal epithelial tight junction induced by platelet activating factor. Inflammation. 2012;35:308-15. Search in Google Scholar

16 Sun Y, Wang L, Zhou Y, Mao X, Deng X. Cloning and characterization of the human trefoil factor 3 gene promoter. PLoS One. 2014;9(4):e95562. Search in Google Scholar

17 Bulitta CJ, Fleming JV, Raychowdhury R, Taupin D, Rosenberg I, Wang TC. Autoinduction of the trefoil factor 2 (TFF2) promoter requires an upstream cis-acting element. Biochem Biophys Res Commun. 2002;293(1):366-74. Search in Google Scholar

18 Aravind K, Poornima T, Sibasis SS, Kumar SA. Prevalence of insulin resistance: a prospective study in North Indian population. Indian J Clin Biochem. 2005;20:10-7. Search in Google Scholar

19 McDougall KE, Stewart AJ, Argiriou AM, Huggins CE, New PW. Comparison of three methods for measuring height in rehabilitation inpatients and the impact on body mass index classification: An open prospective study. Nutr Diet. 2018;75(1):123-8. Search in Google Scholar

20 Marengo-Rowe AJ. The thalassemias and related disorders. In: Baylor university medical center proceedings. Taylor & Francis; 2007:27-31. Search in Google Scholar

21 Galanello R. Recent advances in the molecular understanding of non-transfusion-dependent thalassemia. Blood Rev. 2012;26:S7-11. Search in Google Scholar

22 Koeppen AH. The history of iron in the brain. J Neurol Sci. 1995;134:1-9. Search in Google Scholar

23 Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045-60. Search in Google Scholar

24 Andrews NC. Iron homeostasis: insights from genetics and animal models. Nat Rev Genet. 2000;1(3):208-17. Search in Google Scholar

25 De Jong G, Van Dijk JP, Van Eijk HG. The biology of transferrin. Clin Chim Acta. 1990;190(1-2):1-46. Search in Google Scholar

26 Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11):863-73. Search in Google Scholar

27 Kosaryan M, Aliasgharian A, Mousavi M, Roshan P. Diagnostic value of fructosamine and glycosylated hemoglobin in estimating blood glucose level in diabetic patients with thalassemia major. Med Lab J. 2013;7(3):16-23. Search in Google Scholar

28 Politou M, Kalotychou V, Pissia M, Rombos Y, Sakellaropoulos N, Papanikolaou G. The impact of the mutations of the HFE gene and of the SLC11A3 gene on iron overload in Greek thalassemia intermedia and beta (s)/beta (thal) anemia patients. Haematologica. 2004;89(4):490-2. Search in Google Scholar

29 Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Disorders of hemoglobin: genetics, pathophysiology, and clinical management. Cambridge University Press; 2009. Search in Google Scholar

30 Elmrghni S, Dixon RA, Williams DR. Frequencies of HFE gene mutations associated with haemochromatosis in the population of Libya living in Benghazi. Int J Clin Exp Med. 2011;4(3):200. Search in Google Scholar

31 Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75(3):473-86. Search in Google Scholar

32 Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26(2):19. Search in Google Scholar

33 Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am. 2007;91(6):1063-77. Search in Google Scholar

34 Gallagher EJ, LeRoith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med A J Transl Pers Med. 2010;77(5):511-23. Search in Google Scholar

35 Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17:1-14. Search in Google Scholar

36 Ge H, Gardner J, Wu X, Rulifson I, Wang J, Xiong Y, et al. Trefoil factor 3 (TFF3) is regulated by food intake, improves glucose tolerance and induces mucinous metaplasia. PLoS One. 2015;10(6):e0126924. Search in Google Scholar

37 Fueger PT, Schisler JC, Lu D, Babu DA, Mirmira RG, Newgard CB, et al. Trefoil factor 3 stimulates human and rodent pancreatic islet β-cell replication with retention of function. Mol Endocrinol. 2008;22(5):1251-9. Search in Google Scholar

38 Paulsen FP, Berry MS. Mucins and TFF peptides of the tear film and lacrimal apparatus. Prog Histochem Cytochem. 2006;41(1):1-53. Search in Google Scholar

39 Krüger K, Schmid S, Paulsen F, Ignatius A, Klinger P, Hotfiel T, et al. Trefoil factor 3 (TFF3) is involved in cell migration for skeletal repair. Int J Mol Sci. 2019;20(17):1-13. Search in Google Scholar

40 Otto WR, Thim L. Trefoil factors: Trefoil factor family-interacting proteins. Cell Mol Life Sci C. 2005;62:2939-46. Search in Google Scholar